Breezing

Breezing is a commercial-stage medical device company offering a novel, portable metabolic analyzer. Its FDA-cleared Breezing Med device provides gold-standard indirect calorimetry measurements for personalized weight management and nutritional assessment in clinical settings, with features enabling remote patient monitoring and insurance reimbursement. Founded in 2013 by a team including Mayo Clinic fellows, the company leverages its proprietary sensor technology to disrupt the traditional metabolic cart market with a lower-cost, user-friendly solution validated by leading institutions.

Proprietary indirect calorimetry platform using a disposable, stamp-sized sensor cartridge that simultaneously and accurately measures oxygen (O2) and carbon dioxide (CO2) in breath to calculate Resting Energy Expenditure (REE) and Respiratory Quotient (RQ).

Breezing's primary competition comes from traditional, bulky, and expensive metabolic carts used in hospital labs. It differentiates on portability, cost (1/10th the price), and ease of use. Other competitors include predictive equations and handheld devices that only measure CO2, which are less accurate. Breezing's FDA clearance for measuring both gases is a key competitive moat.